New translational studies are now needed to develop pipelines to take these potential therapeutic agents (cGAS inhibitor, TLR9 antagonist and NAC) closer to clinical trial testing, including further detailed mechanistic studies, dose response curves to determine the most effective concentration of each therapeutic agent and assessment of bio availability in children with JDM or related diseases where appropriate. The gene discussed is TLR9; the disease is juvenile dermatomyositis.